Kymera Therapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Equivalents | $357.0M | $120.3M | $110.0M | $68.4M | $48.0M | $31.0M | $76.0M |
| Accounts Receivable | — | $0 | $15.0M | $0 | — | — | — |
| Inventory | — | — | — | — | — | — | — |
| Total Current Assets | $871.2M | $510.3M | $405.3M | $419.4M | $451.3M | $302.3M | $92.8M |
| Property, Plant & Equipment | $43.2M | $50.5M | $48.1M | $13.3M | $11.9M | $10.8M | $3.8M |
| Goodwill | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — |
| Total Assets | $1.74B | $978.0M | $575.8M | $603.1M | $605.9M | $487.2M | $116.7M |
| Liabilities | |||||||
| Accounts Payable | $4.0M | $6.0M | $7.1M | $4.3M | $4.0M | $4.4M | $3.3M |
| Total Current Liabilities | $83.2M | $67.8M | $85.7M | $71.3M | $92.5M | $110.6M | $34.6M |
| Long-Term Debt | — | — | — | — | — | — | — |
| Total Liabilities | $163.1M | $142.4M | $180.8M | $113.0M | $146.3M | $203.3M | $82.0M |
| Stockholders' Equity | |||||||
| Retained Earnings | $-1.07B | $-754.6M | $-530.8M | $-383.8M | $-229.0M | $-128.8M | $-76.5M |
| Total Stockholders' Equity | $1.58B | $835.6M | $395.0M | $490.2M | $459.6M | $283.9M | $-74.4M |